BioMarin Pharmaceutical Stock Forecast
NASDAQ: BMRNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 54.80 -0.16%
BMRN analyst consensus
Consensus (27 analysts)
buy
Avg. price target
$91.62+66.92%
- Strong buy 6
- Buy 14
- Hold 7
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 27 Wall Street analysts covering BioMarin Pharmaceutical (2026-10-07), 20 rate the stock a buy or strong buy, 7 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $91.62, with a high estimate of $124.00 and a low estimate of $60.00. The average target implies upside of 66.9% from the current price of $54.89.
The spread between the highest and lowest targets is 106.7%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for BMRN.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 6 | 22% |
| Buy | 14 | 52% |
| Hold | 7 | 26% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $60.00 | +9.31% |
| Average target | $91.62 | +66.92% |
| High target | $124.00 | +125.91% |